Symbols

IOVA

Iovance·NASDAQ

--(--)

IOVA fundamentals

IOVA Q4 2025 Earnings

Iovance (IOVA) released its earnings on Feb 24, 2026: revenue was 86.71M (YoY +17.66%), beat estimates; EPS was -0.18 (YoY +30.77%), missed estimates.

Revenue / YoY

86.71M

+17.66%

EPS / YoY

-0.18

+30.77%

Report date

Feb 24, 2026

IOVA Earnings Call Summary for Q4,2025

Revenue Growth: 30% YoY to $264 million, driven by Amtagvi with 50% Q4 gross margin.
Strategic Expansion: FDA fast-track for NSCLC and 50% ORR in sarcomas, targeting $1 billion+ melanoma sales.
Operational Strength: Internalized manufacturing at ICTC extends cash runway to Q3 2027.
Pipeline Momentum: Single-arm sarcoma trial and NSCLC BLA in 2027, with next-gen IL-2 therapies in development.
Community Growth: Community ATCs expected to double in 2026, supporting Amtagvi's $1 billion+ potential.

Earnings

EPS

Revenue

Revenue & Expenses

IOVA has released its 2025 Q4 earnings report, with revenue of 86.77M, reflecting a YoY change of 17.75%, and net profit of -71.90M, showing a YoY change of 8.47%. The Sankey diagram below clearly presents IOVA's revenue sources and cost distribution.

Key Indicators

Iovance (IOVA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Iovance (IOVA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Iovance (IOVA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Iovance (IOVA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown